As recently reported in BioSpectrum, research increasingly indicates that Asia is the preferred destination for clinical trials. The article linked below explains, that “[w]ith its large treatment-naive population, highly skilled investigators, robust clinical infrastructure, faster time to recruit patients, cost efficiencies and the same high-quality output, Asia has emerged as a preferred outsourcing destination.”
Read more here.